Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nilotinib + vincristine + prednisone + doxorubicin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination chemotherapy regimen that includes nilotinib (a tyrosine kinase inhibitor targeting BCR-ABL), vincristine (a vinca alkaloid), prednisone (a corticosteroid), and doxorubicin (an anthracycline). The combination has been studied in clinical trials for various cancers, particularly Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nilotinib inhibits BCR-ABL kinase and may enhance the efficacy of cytotoxic agents by inhibiting MRP-1/P-gp efflux activity. This combination aims to provide synergistic effects on tumor cell growth, apoptosis, and potentially angiogenesis and immunomodulation.
02
Targets
TUBB (Tubulin (alpha and beta subunits))ABCB1 (P-glycoprotein)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)DNAABCC1 (MRP1)TOP2A (DNA topoisomerase II)PDGFR (PDGFR family)GR (Glucocorticoid receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on nilotinib + vincristine + prednisone + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nilotinib + vincristine + prednisone + doxorubicin.